Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Alzheimer's disease (AD) and vascular dementia (VaD) are the most common forms of senile dementia. Although the animal research of dementia has made remarkable progress, clinical trials of drugs for AD pathology have failed in recent years. The study of dementia based on cell and animal model generally aims at a single mechanism and target, and its results are quite different from the real clinical environment. More and more studies suggest that investigators should shift the focus of research to the early stage of cognitive impairment before dementia. Prevention is more important than cure, and intervention against multi-factors and multi-targets has become an important consensus. A large number of studies have shown that the mechanism of vascular brain injury plays an important role in the pathogenesis of AD and VaD, and many vascular risk factors are interventionable to some extent. Therefore, based on the clinical cohort, in-depth study of vascular cognitive impairment (Vascular cognitive impairment, VCI) has important clinical significance for the effective prevention and treatment of AD and VaD.
The leading team of the project has focused on VCI research for a long time. After nearly 20 years of experimental research and preliminary clinical observation, it is proposed that chronic cerebral ischemia can not only be a clinical disease entity, but also an important pathological basis for the early onset of VCI. This view has recently been supported by a number of authoritative international research evidence. Big data's study of 1171 patients with AD reported by Nature Commun in 2016 shows that the early pathological changes of AD may not be a cascade of amyloid protein (Aβ), but a decrease in cerebral blood flow. Therefore, this project intends to establish an early clinical research cohort of VCI to focus on three key issues in VCI research and clinical practice: (1) the theory that cerebral hypoperfusion may be an important pathological basis for the occurrence and development of VCI needs direct evidence support from clinical studies, and its mechanism needs further elucidation. (2) Based on the fusion of multimodal MRI of VCI vascular brain injury pathology and PET imaging markers of Aβ molecular pathology, a multivariate VCI cognitive evaluation model is constructed, and its sensitivity and specificity may be better than the existing VCI diagnostic standards. (3) the protective effect of early comprehensive intervention of vascular risk factors on cognitive decline in VCI may be more effective than that of single risk factor.
The first part of this project is to establish a study cohort of non-demented vascular cognitive impairment(VCIND). Neurocognitive function assessment combined with multimodal MRI including ASL, DCE, DTI and BOLD techniques were used to observe the role of cerebral hypoperfusion in the early stage and progression of VCI. At the same time, the relationship between the changes of blood-brain barrier and neural network and cognitive decline was dynamically observed to verify and explore the effect and mechanism of cognitive impairment caused by cerebral hypoperfusion. The second part studies the pathology of vascular brain injury based on MRI and the molecular pathology of A β based on PET and the relationship between Aβ molecular pathology and cognitive impairment, including the main factors affecting cognitive function, and uses artificial intelligence (AI) algorithm to develop a multiple quantitative evaluation system of VCI cognitive function, which is mainly based on the fusion of MRI and PET image markers. In the third part, a multicenter randomized controlled clinical cohort study was conducted to observe the cognitive protective effect of comprehensive intensive intervention of vascular risk factors on early VCI, so as to provide direct clinical evidence and intervention model for the prevention and treatment of VCI. The topics of the above three aspects covered by this project are closely related, which is not only a key scientific problem, but also an important clinical problem to be solved in the diagnosis and treatment of VCI.
The study of this project is expected to further clarify the role and mechanism of cerebral hypoperfusion in VCI, provide a new theoretical basis for the prevention and treatment of dementia, and develop a quantitative evaluation system of VCI cognitive function mainly based on imaging technology and AI algorithm, so as to provide a more accurate and convenient diagnostic tool for early clinical identification and scientific research of VCI. Draw up the early comprehensive intervention paradigm of VCI based on vascular risk factors and popularize it in clinic, gradually form an expert consensus, enrich and update the guidelines for diagnosis and treatment of dementia, and effectively improve the level of prevention and treatment of dementia related to VCI.
The main research contents of this project focus on the above three key issues: to study the role and mechanism of cerebral hypoperfusion in the early pathogenesis of VCI; to establish a predictive model for early diagnosis of MRI vascular brain damage and PET-A β pathology; to explore the clinical effect of early comprehensive intensive intervention of VRF on the prevention and treatment of VCI.
1. To explore the role and mechanism of cerebral hypoperfusion in the early brain damage of VCI.
2. Early VCI diagnosis prediction model based on imaging technology and its key techniques.
Previous studies have shown that the occurrence and development of VCI is not only closely related to structural MRI indexes such as cerebral infarction, cerebral atrophy and cerebral microvascular disease, but also to functional MRI indexes such as cerebral hypoperfusion and brain ultrastructural damage. However, a VCI quantitative evaluation system based on the above imaging index fusion has not been established at present. On the other hand, up to 40-80% of VCI patients have AD-like pathological changes characterized by Aβ. The impact of Aβ pathology on cognitive decline in patients with VCI and whether A β pathological indicators need to be included in the diagnosis of VCI still need to be clarified in cohort studies. This project intends to use artificial intelligence (AI) algorithm, combined with MRI vascular brain pathological damage and related factors affecting cognitive function, to build a VCI diagnosis prediction model suitable for clinical application, and verify it in the cohort study. At the same time, the Aβ molecular pathological images based on PET were integrated to establish a VCI diagnosis prediction model suitable for clinical scientific research, and further clarify the possible role of Aβ pathology in the occurrence and development of VCI.
3. A cohort study on the effect of comprehensive intervention of vascular risk factors on vascular cognitive impairment.
Study on the effect of early comprehensive intensive intervention on vascular cognitive impairment.
The purpose of this study was to establish a cohort of VCIND (n = 250) and a cohort of cognitive normal people with VRF (n=250). Each cohort was divided into two groups: comprehensive intensive intervention group and general intervention group. Comprehensive intensive intervention provides guidance on blood pressure, blood sugar, lipid regulation, exercise and other aspects according to the corresponding VRF, and formulates specific intervention programs and quality control standards. Medical staff implement tracking management and regular reminders through smart wearable devices and cloud platform data to achieve the goal of gradual intervention. General data, vascular risk factors and neuropsychological assessment were completed at baseline and 1-year, 2-year, 3-year follow-up. Mixed random effect regression model and Cox proportional hazard model were used to analyze the effects of VRF and comprehensive intervention on the outcome of end events (main outcome: dementia, secondary outcome: stroke, myocardial infarction, cognitive impairment, dementia subtype and mortality). According to the Fuminghan stroke risk subgroup, the differences of clinical effects of comprehensive intervention in different subgroups were statistically analyzed.
Effect of comprehensive intensive intervention on early cerebral perfusion and Aβ in patients with vascular cognitive impairment.
At the end of baseline and 3-year follow-up, 50 patients in the VCIND comprehensive intensive intervention group and 50 patients in the general treatment group completed the detection of ASL cerebral blood flow and 11C-PiB PET cerebral Aβ. The effects of comprehensive intensive intervention on cerebral blood flow, Aβ and cognitive function were analyzed. To further analyze the relationship between the changes of cerebral blood flow and A β pathology, as well as its influence on cognitive function, to clarify the target and mechanism of early comprehensive intensive intervention, and to establish a perfect evaluation standard of imaging effect.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Comprehensive intensive intervention | Experimental | On the basis of routine management, carry out individualized cerebrovascular risk factor assessment and comprehensive intervention in a medical-nursing cooperation model, and require corresponding control indicators to be achieved. A comprehensive intervention team is established by specialized medical staff to monitor blood pressure, heart rate, exercise and other data through smart wearable devices, and automatically upload them to the cloud platform, conduct comprehensive data analysis every week, timely feedback and online reminders, establish health management files, and improve the target population The blood-brain tube risk factor control and self-management ability. |
|
| Routine management | No Intervention | Only routine management was carried out for the subjects without special intervention. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Comprehensive intensive intervention | Combination Product |
|
| Measure | Description | Time Frame |
|---|---|---|
| Montreal Cognitive Assessment (MoCA) | The scores of the MoCA tests are used to evaluate the cognitive function of the subjects. MoCA is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA is the most sensitive test available for measuring multiple cognitive domains which are important components not measured by the MMSE. The minimum value of Montreal Cognitive Assessment measurement is 0 and the maximum value is 30. Overall, a worse Moca score represents a worse cognitive function of the participants. | Baseline |
| Montreal Cognitive Assessment (MoCA) | The scores of the MoCA tests are used to evaluate the cognitive function of the subjects. MoCA is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA is the most sensitive test available for measuring multiple cognitive domains which are important components not measured by the MMSE. The minimum value of Montreal Cognitive Assessment measurement is 0 and the maximum value is 30. Overall, a worse Moca score represents a worse cognitive function of the participants. | One-year follow-up |
| Montreal Cognitive Assessment (MoCA) | The scores of the MoCA tests are used to evaluate the cognitive function of the subjects. MoCA is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA is the most sensitive test available for measuring multiple cognitive domains which are important components not measured by the MMSE. The minimum value of Moca measurement is 0 and the maximum value is 30. Overall, a worse Montreal Cognitive Assessment score represents a worse cognitive function of the participants. | Two-year follow-up |
| Montreal Cognitive Assessment (MoCA) | The scores of the MoCA tests are used to evaluate the cognitive function of the subjects. MoCA is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA is the most sensitive test available for measuring multiple cognitive domains which are important components not measured by the MMSE. The minimum value of Montreal Cognitive Assessment measurement is 0 and the maximum value is 30. Overall, a worse Moca score represents a worse cognitive function of the participants. |
| Measure | Description | Time Frame |
|---|---|---|
| Auditory Verbal Learning Test(AVLT) | AVLT is used to measure participantins' instantaneous memory and delayed recall. The minimum value of the Auditory Verbal Learning Test score is 0, and the maximum value is 12 (delayed recall) or 36 ( instantaneous memory). A higher score means better cognitive function. | Baseline |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Junjian Zhang, Ph. D. | Contact | 13986225751 | xsssm@sina.com |
| Name | Affiliation | Role |
|---|---|---|
| Zhipeng Xu, Ph. D. | Zhongnan Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Zhongnan Hospital | Recruiting | Wuhan | Hubei | 430071 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42056952 | Derived | He J, Song H, Zhang J. Association between neutrophil percentage-to-albumin ratio and vascular cognitive impairment in patients with cerebrovascular disease: a cross-sectional study. BMC Neurol. 2026 Apr 29;26(1):387. doi: 10.1186/s12883-026-04937-y. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Three-year follow-up |
| Mini-Mental State Examination(MMSE) | MMSE is used as a screening scale for cognitive impairment, can measure the participants' global cognitive function. The minimum value of the Mini-Mental State Examination measurement value is 0 and the maximum value is 30. A worse MMSE score represents a worse cognitive function of the participants. | Baseline |
| Mini-Mental State Examination(MMSE) | MMSE is used as a screening scale for cognitive impairment, can measure the participants' global cognitive function. The minimum value of the Mini-Mental State Examination measurement value is 0 and the maximum value is 30. A worse MMSE score represents a worse cognitive function of the participants. | One-year follow-up |
| Mini-Mental State Examination(MMSE) | MMSE is used as a screening scale for cognitive impairment, can measure the participants' global cognitive function. The minimum value of the Mini-Mental State Examination measurement value is 0 and the maximum value is 30. A worse MMSE score represents a worse cognitive function of the participants. | Two-year follow-up |
| Mini-Mental State Examination(MMSE) | MMSE is used as a screening scale for cognitive impairment, can measure the participants' global cognitive function. The minimum value of the Mini-Mental State Examination measurement value is 0 and the maximum value is 30. A worse MMSE score represents a worse cognitive function of the participants. | Three-year follow-up |
| Auditory Verbal Learning Test(AVLT) |
AVLT is used to measure participantins' instantaneous memory and delayed recall. The minimum value of the Auditory Verbal Learning Test score is 0, and the maximum value is 12 (delayed recall) or 36 ( instantaneous memory). A higher score means better cognitive function. |
| One-year follow-up |
| Auditory Verbal Learning Test(AVLT) | AVLT is used to measure participantins' instantaneous memory and delayed recall. The minimum value of the Auditory Verbal Learning Test score is 0, and the maximum value is 12 (delayed recall) or 36 ( instantaneous memory). A higher score means better cognitive function. | Two-year follow-up |
| Auditory Verbal Learning Test(AVLT) | AVLT is used to measure participantins' instantaneous memory and delayed recall. The minimum value of the Auditory Verbal Learning Test score is 0, and the maximum value is 12 (delayed recall) or 36 ( instantaneous memory). A higher score means better cognitive function. | Three-year follow-up |
| Verbal Fluency Test (VFT) | Verbal fluency test is used to measure language ability. The minimum value of the Verbal Fluency Test score is 0. A higher score represents a better language function. | Baseline |
| Verbal Fluency Test (VFT) | Verbal fluency test is used to measure language ability. The minimum value of the Verbal Fluency Test score is 0. A higher score represents a better language function. | One-year follow-up |
| Verbal Fluency Test (VFT) | Verbal fluency test is used to measure language ability. The minimum value of the Verbal Fluency Test score is 0. A higher score represents a better language function. | Two-year follow-up |
| Verbal Fluency Test (VFT) | Verbal fluency test is used to measure language ability. The minimum value of the Verbal Fluency Test score is 0. A higher score represents a better language function. | Three-year follow-up |
| Clock Drawing Test(CDT) | CDT is used to measure visual space ability. The minimum value of the Clock Drawing Test score is 0 and the maximum value is 15. A test score lower than 12 means that the participant's visual space function is impaired. | Baseline |
| Clock Drawing Test(CDT) | CDT is used to measure visual space ability. The minimum value of the Clock Drawing Test score is 0 and the maximum value is 15. A test score lower than 12 means that the participant's visual space function is impaired. | One-year follow-up |
| Clock Drawing Test(CDT) | CDT is used to measure visual space ability. The minimum value of the Clock Drawing Test score is 0 and the maximum value is 15. A test score lower than 12 means that the participant's visual space function is impaired. | Two-year follow-up |
| Clock Drawing Test(CDT) | CDT is used to measure visual space ability. The minimum value of the Clock Drawing Test score is 0 and the maximum value is 15. A test score lower than 12 means that the participant's visual space function is impaired. | Three-year follow-up |
| Trail Making Test(TMT) | The Trail Making Test is used as an indicator of visual scanning, graphomotor speed, and executive function. The time taken by the participants to complete the Trail Making Test and the number of errors during the test need to be recorded. The longer the participants spend, the more errors they make, and the worse their executive function is. | Baseline |
| Trail Making Test(TMT) | The Trail Making Test is used as an indicator of visual scanning, graphomotor speed, and executive function. The time taken by the participants to complete the Trail Making Test and the number of errors during the test need to be recorded. The longer the participants spend, the more errors they make, and the worse their executive function is. | One-year follow-up |
| Trail Making Test(TMT) | The Trail Making Test is used as an indicator of visual scanning, graphomotor speed, and executive function. The time taken by the participants to complete the Trail Making Test and the number of errors during the test need to be recorded. The longer the participants spend, the more errors they make, and the worse their executive function is. | Two-year follow-up |
| Trail Making Test(TMT) | The Trail Making Test is used as an indicator of visual scanning, graphomotor speed, and executive function. The time taken by the participants to complete the Trail Making Test and the number of errors during the test need to be recorded. The longer the participants spend, the more errors they make, and the worse their executive function is. | Three-year follow-up |